U.S. markets closed

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
27.27-0.04 (-0.15%)
At close: 4:00PM EDT
27.27 0.00 (0.00%)
After hours: 04:01PM EDT
Sign in to post a message.
  • d
    dc
    sure are beating up healtcare biotech....fwrd pe for sector is low compared to others....
  • P
    P
    Probably some very good news coming...Tends to get dragged down to allow a cheap entry point for the Hedgies and others and to keep control of the Share price when there is important material news...Lets see!
  • l
    longvrts
    Report out: Viloxazine- ER PIII trial results in childrean and adolescents published. Excellent efficacy and safety reported from 4 trials:

    Neuropsychiatr Dis Treat. 2021 Jun 3;17:1751-1762. doi: 10.2147/NDT.S312011. eCollection 2021.

    The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials

    Azmi Nasser 1, Joseph T Hull 1, Tesfaye Liranso 2, Gregory D Busse 3, Zare Melyan 3, Ann C Childress 4, Frank A Lopez 5, Jonathan Rubin 6

    Affiliations
    1Department of Clinical Research, Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
    2Department of Biostatistics, Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
    3Department of Medical Affairs, Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
    4Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV, USA.
    5Children's Developmental Center, Winter Park, FL, USA.
    6Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
    PMID: 34113106 PMCID: PMC8184252 DOI: 10.2147/NDT.S312011
    Free PMC article

    Abstract
    Purpose: The ADHD Rating Scale (ADHD-RS) assesses 18 symptoms of inattention and hyperactivity/impulsivity and has been used in many clinical trials to evaluate the treatment effect of drugs on ADHD. The fifth edition of this scale (ADHD-RS-5) also assesses the impact of inattention and hyperactivity/impulsivity symptoms on six domains of functional impairment (FI): family relationships, peer relationships, completing/returning homework, academic performance at school, controlling behavior at school, and self-esteem. Here, we report the effect of viloxazine extended-release capsules (viloxazine ER), a novel nonstimulant treatment for ADHD in children and adolescents (ages 6-17 years), on FI from a post hoc analysis of four randomized, double-blind, placebo-controlled Phase 3 clinical trials (N=1354).

    Patients and methods: ADHD-RS-5 investigator ratings of ADHD symptoms and FIs were conducted at baseline and weekly post-baseline for 6-8 weeks in the four trials. Change from baseline (CFB) in ADHD-RS-5 FI scores (Total score [sum of 12 FI items] and Inattention and Hyperactivity/Impulsivity subscale scores [sum of 6 corresponding FI items]) and the 30% and 50% Responder Rates (ADHD-RS-5 FI Total score) were compared between viloxazine ER and placebo.

    Results: The reduction (improvement) in ADHD-RS-5 FI scores (Total and subscale scores) and the percentage of responders (30% and 50%) at Week 6 were significantly greater in each viloxazine ER dose group vs placebo. In the 100-400 mg/day viloxazine ER groups, improvements were found as early as Week 1 (100-mg/day) or Week 2 (200-, 400-mg/day) of treatment. Analysis of individual items of ADHD-related FIs demonstrated that the effect of viloxazine ER was observed across all domains of impairment.

    Conclusion: Significant improvements observed in ADHD-related FIs are consistent with the reduction in inattention and hyperactivity/impulsivity symptoms demonstrated in the viloxazine ER Phase 3 pediatric trials. Therefore, viloxazine ER provides clinically meaningful improvement of ADHD symptoms and functioning in children and adolescents with ADHD, starting as early as Week 1-2 of treatment.
  • m
    mike
    Congratulations to us Longs on SUPN. Finally this under appreciated undervalued company is getting some attention. SUPN is up over $2.00 as I type this post and I don’t see one new post on the SUPN message board.
    Even at the current price SUPN is very undervalued.
  • d
    dc
    the safest bet in the market today.....yet up .02c move....
    I'll say it again, this is a MM carry trade type symbol, 105% institutional ownership, that kind of control is exactly why stock is stuck here.....they trade between each other and decide if the shorts get some cash today or some longs.....
  • D
    DW
    What's with the after hours 13% drop?
  • e
    edu
    the financial reports say its a good business, and now is the time to buy, but i wont buy it because i dont understand the business.
  • P
    P
    The Fed and all this BS about whether Jay Powell knows what he's doing knocked the MoMo
    out this move....Pity, really thought it would at least pass $35 ...The amount of crud coming out
    of cnbc commentators mouths especially Sarah Icecream (brain!) on the closing bell drives me up the wall.

    Oh Well theres always tomorrow ...!!!! Long and strong SUPN!!
  • Y
    Yahoo Finance Insights
    Supernus Pharmaceuticals is up 6.11% to 33.87
  • P
    P
    Wall St. is on vacay ....See the volume everywhere today...
  • P
    P
    This maybe ...Just maybe, getting close to a long deserved breakout....Holding up very well in
    this crazy market.....
  • m
    mike
    SUPN reported 38% revenue growth over last years 1st quarter. Outstanding
  • P
    P
    Very...VERY! Good earnings call from Mr. Khattar last night....Hard to call what the stock will do today after those earnings numbers, but the medium term future looks pretty bright! (6 to 12 months and beyond!) I'm gonna guess up today and even higher when we get some analyst comments in the next few days ...Long and strong Supn!
  • j
    jim
    This is a solid company with nothing but positives year over year. SUPN meets the normal “check box” for a quality investment (with exception of no DIV). I attribute the low price due to the shares being vastly owned by institutions and when coupled with generally low volume...it affects the price of the stock when these investors make a move. Considering the current sentiment of the market, institutional investors are reducing equity positions in anticipation of slowing economy/end of market cycle (if not recession). I think most made this move last year, so not much more downside than this.
    This presents a BUY opportunity for us retail investors.
    I’m in at limit buys of: $35.50, $34, and large final position at $30.
    Bullish on the long position.
    Bullish
  • l
    longvrts
    4/2 SUPN News:

    Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

    Supernus Pharmaceuticals, Inc.
    Fri, April 2, 2021, 1:58 PM

    Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade

    Supernus plans to make Qelbree available in the U.S. in 2Q 2021

    ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.

    “Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD,” said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “Qelbree provides prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile. We are grateful to the patients, families and their care givers who participated in and supported our research.”

    “ADHD is one of the most common mental health issues in the U.S.,” said Andrew J. Cutler, M.D., Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University, and Chief Medical Officer, Neuroscience Education Institute. “The right treatment is key for children and adolescents, as they grow and navigate school and social relationships. This approval offers a novel once a day sprinkleable non-stimulant that can be a great option for children and adolescents with ADHD.”

    The approval of Qelbree is supported by data from an extensive development program consisting of four Phase III clinical trials that studied more than 1000 pediatric patients from the age of 6 to 17 years. In December 2020, the Company announced positive results from a Phase III trial in adult patients with ADHD and plans to submit a supplemental New Drug Application to the FDA for Qelbree in adults in the second half of 2021.
  • Q
    QuantumAnteater
    $NEOS conversation
    Supernus buys CNS portfolio for $530M. I guess that would make $NEOS buyout by $SUPN in near future less likely.

    https://seekingalpha.com/news/3565707-supernus-buys-cns-portfolio-for-530m
    Supernus Pharmaceuticals (NASDAQ:SUPN) agrees to acquire the central nervous system portfolio of US WorldMeds, a privately held biopharmaceutical company, for $530M.Price consists of a $300M upfront c
    Supernus Pharmaceuticals (NASDAQ:SUPN) agrees to acquire the central nervous system portfolio of US WorldMeds, a privately held biopharmaceutical company, for $530M.Price consists of a $300M upfront c
    seekingalpha.com
  • A
    Andy
    Wow, 11 cents per share is rather paltry for a company that is at $30 per share. This is a huge miss when prior year was 40 cents per share and even analysts consensus was expecting 24 cents per share. Something is broken in SUPN. They are heading down. Maybe SUPN will see $15 per share this quarter.
    Bearish
  • R
    Richard
    Clayton, I've been in since 2012 with a $8 average, holding until $75-$100 or buyout.
    Richard
  • l
    longvrts
    SUPN beats on EPS, revenue; positive guidance for '19; pipeline advancing nicely. IMO: Based on the above, SUPN poised to see significant pps appreciation in '19.
  • l
    longvrts
    SUPN beats by +174% on EPS; by 18% on revenue.
    Guides upward for '20: $500-525 Million in revenues; $145-160 Million in earnings.
    Great prospects in '21 and beyond.